Lupus Clinical Trials

A research study is evaluating an investigational medication in addition to standard treatment for adults with Systemic Lupus Erythematosus (SLE).  

The purpose of this study is to see if the study drugs, ABBV-105, upadacitinib (ABT-494), or both ABBV-105 and upadacitinib (ABT-494) in combination (ABBV-599) are safe, tolerable, and effective in treating your moderately to severely active systemic lupus erythematosus (SLE).  

Cancer is the second-leading cause of death in the United States today. The majority of cancer deaths can be attributed to the metastatic spread of solid tumors to distant organs. Medical progress in the last century has aided in the earlier identification of cancers limited to the primary organ and ...

This study is taking place at our Clearwater, FL office. It is for patients diagnosed with mild to moderate and moderate to severe lupus.  

A research study is evaluating an investigational medication combined with standard treatment that may improve symptoms associated with lupus.  

Local doctors are looking for adults struggling with lupus for clinical research studies of an investigational medication. Doctors are studying this medication to see if it may provide relief with common symptoms associated with lupus.  

This study is designed to evaluate genetic mechanisms of lung disease by surveying polymorphic genes involved in respiratory function and examining gene expression in the lung cells of individuals with pulmonary disease (e.g., alpha 1-antitrypsin deficiency, asthma, chronic obstructive pulmonary disease, cystic fibrosis, sarcoidosis, history of infection, and genetic mutations ...

This is a randomized, placebo controlled, double blind study. Following a screening period of up to 28 days, subjects with active systemic lupus erythematosus (SLE) including moderate to severe rash and/or arthritis despite corticosteroid therapy will be randomized in a 1:1 ratio to receive 1 mL (80 Units [U]) of ...

The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for ...

The purpose of this clinical trial is to determine whether an investigational treatment, when added to either rituximab or cyclophosphamide, can improve your vasculitis disease activity, kidney function, and/or quality of life.